Venus Remedies secures marketing authorisations for key oncology drugs from Morocco
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Developed in consultation with clinicians and patients for an enhanced user experience
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
NMC to continue its efforts to improve and enhance the quality of medical education in the country
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Subscribe To Our Newsletter & Stay Updated